Frank L. Meyskens Jr,MD

picture of Frank L. Meyskens

Distinguished Professor, College of Health Sciences
School of Medicine

Founding,Director Emeritus, and Senior Advisor, Chao Family Comprehensive Cancer Center

M.D., University of California, San Francisco, 1972
B.S., University of San Francisco, 1967

Phone: (949) 861-0230
Fax: (949) 509-5153

University of California, Irvine
101 The City Drive South
Building 200, Room 427
Mail Code: 4061
Orange, CA 92868
Research Interests
Melanoma (human) – benign and malignant growth – signal transduction, redox metabolism
Academic Distinctions
6/3/2016 Clinical Translational Scientist Career Achievement Award; Institute of Clinical Translational Science, UC Irvine
10/9/2015 Recognition of Career Achievements and Contributions to Southwest Oncology Group, Chicago, IL
7/1/2015 – 6/30/2016 Overall planning and Chairmanship of 19th Annual Meeting of Pan American Society Pigment Cell Research (PASPCR); Orange, CA (meeting held 9/27/15-9/30/2015)
2015 2018 World Affairs Council of Orance County - Counsel/Ambassador; Elected as Trustee
2012 The C. Ronald Koons, M.D. Humanitarian Award to Linda Davidson-Meyskens and Frank L. Meyskens, Jr., M.D., UC Irvine
2012 Arthur Frost Faculty Alumni Award, University of San Francisco
2010 – 2013 Selected for Faculty of 1000
2009 – Present Elected to Royal Society of Medicine (Oversees Fellow)
2008 Hiranandini Oration and Lecture; Puri, India
2008 AACR - Annual Cancer Prevention Foundation Award
2008 – 2013 America’s Top 100 Doctors for Cancer (Castle Connelly)
2007 – 2015 Best Doctors in America
2012 – 2013 US News and World Report’s Top 1% of Physicians
2007 – 2016 Associate Chair of Cancer Control and Prevention- SWOG/NCORP
2006 – Present Daniel G. Aldrich Jr., Endowed Chair
2006 Distinguished Achievement Award, American Society of Preventive Oncology
2007 – 2010 President Pan Am Society for Pigment Cell Research
2004 Chair 12th Annual Conference Pan American Society of Pigment Cell Research, June 24-26, 2004
2003 1st Annual Inaugural Memorial Sydney E. Salmon Award in Translational Cancer Research (Arizona Cancer Center), May 8, 2003, Tucson, AZ
2000 – Present Alpha Omega Alpha, Elected to Faculty Membership (UC Irvine)
2000 Lauds & Laurels Faculty Research Achievement Award (UC Irvine)
1999 – 2004 President, International Society of Cancer Chemoprevention (Immediate Past President 2004-2010)
1996 – 2014, 2017 Best Doctors in Orange County (Orange Coast Magazine)
Research Abstract
We are studying the basis of drug resistance of melanoma cells with a particular interest in Ref-1/APE and redox regulation. We have also proposed an alternative model for the etiology and progression of cutaneous melanoma based on the altered redox metabolism in human melanoma cells and developed new anticancer therapies based on these observations.

We are heavily involved in Phase I, II, and III clinical chemoprevention trials involving oral, colon, pancreas cancer, and melanoma and study such compounds as difluromethiornithine, Bowman-Birk Inhibitors (a Soybean-derived compound) SAMe, and Lovastatin.
Peer Review:

Meyskens, F.L., Jr., McNulty, S.E., Buckmeier, J.A., Tohidian, N.B., Spillane, T.J., Kahlon, R.S., Gonzalez, R.I. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med. 2001 Sep 15;31(6):799-808. (50%) PMID: 11557318.
McNulty, S., Tohidian, N.B., Meyskens, F.L., Jr. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res. 2001 Dec;14(6):456-65. (25%) PMID: 11775058.
Keefe, K.A., Schell, M.J., Brewer, C.B., McHale, M., Brewster, W., Chapman, J.A., Rose, G.S., McMeeken, S., Lagerberg, W., Peng, Y.M., Wilczynski, S.P.O, Anton-Culver, H., Meyskens, F.L., Jr., Berman, M.L. A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1029-35.. (10%) PMID: 11588128.

Cen, D., Gonzalez, R., Buckmeier, J., Kahlon, R., Tohidian, N.B., Meyskens, F.L, Jr. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther. 2002 Jan;1(3):197-204. (20%) PMID: 12467214.

Agarwala, S., Glaspy, J., O’Day, S., Mitchell, M., Gutheil, J., Whitman, E., Gonzalez, R., Hersh, E., Feun, L., Belt, R., Meyskens, F.L., Jr., Hellstrand, K., Wood, D., Kirkwood, J., Gehlsen, K., Naredi, P. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 1;20(1):125-33. (5%) PMID: 11773161.

Farmer, P.J., Gidanian, S., Shahandeh, B., Di Bilio, A.J., Tohidian, N., Meyskens, F.L., Jr. Melanin as a target for melanoma chemotherapy: Pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res. 2003 Jun;16(3):273-9. (20%) PMID: 12753401.

Chan, J.K., Monk, B.J., Brewer, C., Keefe, K.A., Osann, K., McMeekin, S., Rose, G.S., Wilczynski, S.P., Meyskens, F.L,, Jr., Berman, M.L. HPV Infection and Number of Lifetime Sexual Partners Are Strong Predictors for Natural Regression of Untreated Cin II and III. Br J Cancer. 2003 Sep 15;89(6):1062-6. (5%) PMID: 12966426.

Armstrong, W.B., Wan, X.S., Kennedy, A.R., Taylor, T.H., Meyskens, F.L., Jr. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope. 2003 Oct;113(10):1687-702. (10%) PMID: 14520092.

Linden, K.G., Carpenter, P.M., McLaren, C.E., Barr, R.J., Hite, P., Sun, J.D., Li, K.T., Viner, J.L., Meyskens, F.L., Jr. Chemoprevention of Non-melanoma a Skin Cancer: Experience with a Polyphenol from Green Tea. Recent Results Cancer Res. 2003;163:165-71; discussion 264-6. (20%) PMID: 12903852.

Chu, D.Z., Chansky, K., Alberts, D.S., Meyskens, F.L., Jr., et al. Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study. Ann Surg Oncol. 2003 Oct;10(8):870-5. (10%) PMID: 14527904.

McNulty, S., del Rosario, R., Cen, D., Meyskens, F.L., Jr., Yang, S. Comparative Expression of NFkB Proteins in Melanocytes of Normal Skin vs. Benign Intradermal Naevus and Human Metastatic Melanoma Biopsies. Pigment Cell Research 17:173-180, 2004. (20%)

Yang, S., McNulty, S., Meyskens, F.L., Jr. During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. Pigment Cell Res. 2004 Feb;17(1):74-83. (20%) PMID: 14717848.

Yang, S., Meyskens, F.L., Jr. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol Pharmacol. 2005 Jan;67(1):298-308. Epub 2004 Oct 18.(30%) PMID: 15492115.

Carpenter, P., Linden, K., McLaren, C., Li, K.T., Arain, S., Barr, R., Hite, P., Sun, J., Meyskens, F.L., Jr. Nuclear morphometry and molecular biomarker of actinic keratosis, sun-damaged and non-exposed skin. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1996-2002. (10%) PMID: 15598753.

Meyskens, F.L., Jr., Farmer, P., Anton-Culver, H. Etiologic Pathogenesis of Melanoma: A Unifying Hypothesis for the Missing Attributable Risk. Clin Cancer Res. 2004 Apr 15;10(8):2581-3. PMID: 15102657.

Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Meyskens, F.L., Jr., Omenn, G.S., Valanis, B., Williams, J.H. Incidence of lung cancer and cardiovascular disease in CARET: 6-years of follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50. PMID: 15572756.

Cen, D., Brayton, D., Shahandeh, B., Meyskens, F.L., Jr., Farmer, P.: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004 Dec 30;47(27):6914-20. PMID: 15615540.

Hansen, L.K., Feigl, P., Modiano, M.R., Lopez, J.A., Sluder, S.E., Moinpour, C.M., Pauler, D.K., Meyskens, F.L., Jr. An educational program to increase cervical and breast cancer screening in Hispanic women: a Southwest Oncology Group study. Cancer Nurs. 2005 Jan-Feb;28(1):47-53. PMID: 15681982.

Meyskens, F.L., Jr., Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1366-9. PMID: 15941942.

Yang, S, Irani, K., Heffron, S.E., Jurnak, F., Meyskens, F.L., Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther. 2005 Dec;4(12):1923-35. PMID: 16373707.

Misner, B., Meyskens, F.L., Jr. Alterations of Activating Protein-1 (AP-1) in Mouse, JB6P Series Cells. J. of Undergraduate Research in the Biological Sciences. Jun: 36:316-327, 2006.

Keloff, G., Lippman, S., Dannenberg, A., Sigman, C., Pearce, H., Reid, B., Szabo, E., Jordan, C., Spitz, M., Mills, G., Papadimitrakopoulou, V., Lotan, R., Aggarwal, B., Bresalier, R., Kim, J., Arun, B., Lu, K., Thomas, M., Hodes, H., Brewer, M., Follen, M., Shin, D., Parnes, H., Siegfried, J., Evans, A., Lot, W., Chow, W., Blount, P., Maley, C., Wang, K., Lam, S., Lee, J., Dubinett, S., Engstrom, P., Meyskens, F.L., Jr., O’Shaughnessy, J., Hawk, E., Levin, B., Nelson, W., Hong, W. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer – A Plan to Move Forward. Clin Cancer Res. 2006 Jun 15;12(12):3661-97. PMID: 16778094.

Meyskens FL. Jr, Berwick M. UV or not UV: metals are the answer. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):268-70. PMID: 18268109.

Elmore, E., Jain, A., Siddiqui, S., Tohidian, N., Meyskens, F.L., Jr., Steele, V.E., Redpath, J.L. Development and Characteristics of a Human Melanocyte Cell Assay or Screening Agents for Melanoma Prevention. Melanoma Res. 2007 Feb;17(1):42-50. PMID: 17235241.

Yang, S., Misner, B., Chiu, R., Meyskens, F.L. Jr. Redox Effector Factor-1, Combined with Reactive Oxygen Species, Plays an Important Role in the Transformation of JB6 Cells. Carcinogenesis. 2007 Nov;28(11):2382-90. Epub 2007 Jun 12. PMID: 17566060.

Zoumas-Morse, C., Rock, C.L., Quintana, E.L., Neuhouser, M.L., Gerner, E.W., Meyskens, F.L., Jr. Development of a polyamine database for assessing dietary intake. J Am Diet Assoc. 2007 Jun;107(6):1024-7. PMID: 17524725.

Kasuno, K., Naqvi, A., Dericco, J., Yamamori, T., Santhanam, L., Matttagajasingh, I., Yang, S., Meyskens, F.L., Jr., Bosserhoff, A.K., Irani, K. Antagonism of p66shc by melanoma inhibitory activity. Cell Death Differ. 2007 Aug;14(8):1414-21. Epub 2007 Apr 13. PMID: 17431427.

Ghajar, C.M., Suresh, V., Peyton, S.R., Raub, C.B., Meyskens, F.L., Jr, George, S.C., Putnam, A.J. A novel three-dimensional model to quantify metastatic melanoma invasion. Mol Cancer Ther. 2007 Feb;6(2):552-61. Epub 2007 Jan 31. PMID: 17267658.

Yang, S., Misner, B., Chiu, R., Meyskens, F.L., Jr. Common and Distinct Mechanisms of Different Redox active Carcinogens Involved in the Transformation of Mouse JB6P+ Cells. Mol Carcinog. 2008 Jul;47(7):485-91. PMID: 18092320.

Zell, J.A., Cinar, P., Mobasher, M., Ziogas, A., Meyskens, F.L., Jr., Anton Culver, H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J. Clin. Oncol, 2008 Jan 1;26(1):66-75. PMID: 18165642.

Ngo-Metzger, Q., August, K.J., Srinivasan, M., Liao, S., Meyskens, F.L., Jr. End-of-Life care: guidelines for patient-centered communication. Am. Fam. Physician. 2008 Jan 15; 77(2):167-74. PMID: 18246886.

Simoneau, A.R., Gerner, E.W., Nagle, R., Ziogas, A., Fujikawa-Brooks, S. Yerushaimi, H., Ahlering, T.E., Lieberman, R., McLaren, C.E., Anton-Culver, H. Meyskens, F.L., Jr. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol. Biomarkers Prev. 2008 Feb;17(2):292-9. PMID: 18268112.

Gidanian, S., Mentelle, M., Meyskens, F.L., Jr., Farmer, P.J. Melanosomal Damage in Normal Human Melanocytes Inducted by UVB and Metal Uptake-A Basis for the Pro-oxidant State of Melanoma. Photochem. Photobio. 2008 Apr 23;84(3):556-564. PMID: 18331399.

Meyskens, F.L., Jr., McLaren, C.E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P., Hawk, E., Kelloff, G., Lawson, M.J., Kidao, J., McCracken, J., Albers, C.G., Ahnan, D.J., Turgeon, D.K., Goldschmid, S., Lanoe, P., Hagedorn, C.H., Gillan, D.L., Gerner, E.W. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A randomized placebo-controlled, Double-Blind Trial. Cancer Prev Res June1:15-32, 2008. PMID: 18841250.

Yang S., Meyskens, F.L., Jr. Apurinic/apyrimidinic endonuclease /redox effector factor-1(APE/Ref-1) a unique target for the prevention and treatment of human melanoma. Antioxid Redox Signal. 11:639-650 2009 2008 Aug 20. PMID: 18715151.

McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL Jr. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res 2008 Dec;1(7):514-21. PMID: 19139001.

Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL Jr. Nitric oxide initiates progression of human melanoma via a feedback loop medited by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther. 2008 Dec;7(12):3751-60. PMID: 19074850.

Lippman SM, Klein EA, Goodman PF, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Leiber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009 Jan 7;301(1):39-51. PMID: 19066370.
Liu F, Fu Y, Meyskens FL Jr. MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J Invest Dermatol. 2009 Feb;129(2):422-31 PMID: 18971960

Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila). 2009 Mar;2(3):209-12. doi: 10.1158/1940-6207.CAPR-08-0203. Epub 2009 Mar 3. PMID: 19258540.

Taylor TH, Armstrong WB, Meyskens FL. The effectiveness of chemoprevention agents is underestimated when lesion sizes are rounded. Cancer Prev Res (Phila). 2010 Feb;3(2):136-9. doi: 10.1158/1940-6207.CAPR-09-0114. Epub 2010 Jan 19. PMID: 20086183.

Thompson PA, Wertheim BC, Zell JA, Pin Chen W, McLaren CE, Lafleur BJ, Meyskens FL, Gerner, EW. Levels of Rectal Mucosal Polyamines and Prostaglandin E2 Predict Ability of Difluoromethylornithine and Sulindac to Prevent Colorectal Adenoma. Gastroenterology. 2010 Sep;139(3):797-805, 805.e1. doi: 10.1053/j.gastro.2010.06.005. Epub 2010 Jun 9. PMID: 20538001.

Liu F. Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL Jr. MiTF links Erk 1/2 kinase and p21CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cellsMol Cancer. 2010 Aug 11;9:214. doi: 10.1186/1476-4598-9-214. PMID: 20701798.

Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst. 2010 Oct 6;102(19):1513-6. doi: 10.1093/jnci/djq325. Epub 2010 Aug 26. PMID: 20798393.

Garcia AM, McLaren CE, Meyskens FL Jr. Melanoma: is hair the root of the problem? Pigment Cell Melanoma Res. 2011 Feb;24(1):110-8. doi: 10.1111/j.1755-148X.2010.00782.x. Epub 2010 Oct 21. PMID: 20880199.

Meyskens FL, Jr., Curt GA, Brenner DE, Gordon G, Gerberman RB, Finn O, Kelloff GJ, Khief SN, Sigman CC, Szabo E. Regulatory Approval of Cancer-Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic. Cancer Prevention Research. 2011 Mar;4(3):311-323 PMID: 21372031.

Carroll RE Benya RV, Turgeon D, Vereed S, Newman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Jr. Brenner DE. Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal NeoplasiaCancer Prev Res (Phila). 2011 Mar;4(3):354-64. doi: 10.1158/1940-6207.CAPR-10-0098. PMID: 21372035.

Meyskens FL, Yang.S. Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in pointRecent Results Cancer Res. 2011;188:65-74. doi: 10.1007/978-3-642-10858-7_5. PMID 21253789.

Lipkin S, Lee J, Imagawa D, Hewitt SM, Tucker C, Zell JA, Wong V, Garcia A, Gonzales R, Della Zanna G Richmond E, Rodreguez LM, Bigg M, Schnoll-Sussmans F, Meyskens F. Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasmsCancer Prev Res (Phila). 2011 Apr;4(4):512-3. doi: 10.1158/1940-6207.CAPR-10-0373. PMID: 21464031.

Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, Beach T, Monforte J, McClelland M, Mercola D. Diagnosis of prostate cancer using differentially expressed genes in stromaCancer Res. 2011 Apr 1;71(7):2476-87. doi: 10.1158/0008-5472.CAN-10-2585. PMID: 21459804.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, WHI Investigators, Colaborators: Meyskens F Jr. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382. PMID: 21467283.

Chu DZ, Hussey MA, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), Randomized and Placebo Controlled: The Importance of Multiple Luminal Lesions. Clin Colorectal Cancer. 2011 Dec;10(4):310-6. doi: 10.1016/j.clcc.2011.06.005. Epub 2011 Jul 22. PMID: 21782524.

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gazaino JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437. PMID: 21990298.

Liu F, Gomez Garcia AM, Meyskens FL Jr. NADPH Oxidase 1 Overexpression Enhances Invasion via Matrix Metalloproteinase-2 and Epithelial-Mesenchymal Transitions in Melanoma Cells. J Invest Dermatol. 2012 Aug;132(8):2033-41. doi: 10.1038/jid.2012.119. Epub 2012 Apr 19. PMID: 22513785.

Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas. Cancer Causes Control. 2012 Oct;23(10):1739-44. doi: 10.1007/s10552-012-0051-6. Epub 2012 Aug 21. PMID: 22907422.

Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE, Shumaker SA, Meyskens FL, Thompson IM. Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2012 Sep 19;104(18):1373-85. Epub 2012 Sep 12. PMID: 22972968.

Dellinger RW, Matundn HH, Ahmed AS, Duong PH, Meyskens FL Jr. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. PLoS One. 2012;7(10):347676. doi: 10.1371/journal.pone.0047696. Epub 2012 Oct 22. PubMed PMID: 23110092.

Liu F, Bessonova L, Taylor TH, Ziogas A, Meyskens FL Jr, Anton-Culver H. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res. 2013 Jan;26(1):128-35. Doi: 10.1111/pcmr.12035. Epub 2012 Nov 21. PubMed PMID: 23095171

Yang Z, Misner B, Ji H, Poulos TL, Silverman RB, Meyskens FL, Yang S. Targeting Nitric Oxide Signaling with nNOS Inhiabitors As a Novel Strategy for the Therapy and Preventgion of Human Melanoma. Antioxid Redox Signal. 2013 Aug 10;19(5):433-47. doi: 10.1089/ars.2012.4563. Epub 2013 Jan 18. PubMed PMID: 23199242.

Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer. 2013 Feb 19;108(3):512-8. Doi: 10.1038/bjc.2013.15. Epub 2013 Jan 22. PubMed PMID: 23340449.

Xie L, Meyskens FL Jr. The pan-Aurora kinasae inhibitor, PHA-739358, iduces apoptosis and inhibits migration in melanoma cell lines. Melanoma Res. 2013 Apr;23(2): 102-13. Doi: 10.1097/CMR.Ob013e32835df5e4. PubMed PMID: 23344158

Krasieva TB, Stringari C, Liu F, Sun CH, Kong Y, Balu M, Meyskens FL, Gratton E, Tromberg BJ. Two-photon excied fluorescence lifetime imaging and spectroscopy of melanins in vitro and in vivo. J Biomed Opt. 2013 Mar;18(3):31107. doi: 10.1117/1.JBO.18.3.031107.. PubMed PMID: 23235925.

Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, GU M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL Jr. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013 May;6(5):410-8. doi: 10.1158/1940-6207.CAPR-13-0004. PMID:23639862.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi G,Meyskens FL, Albain KS. Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. J Clin Oncol. J Clin Oncol. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.PMID:23733756.

Goodman PJ, Hartline JA, Tangen CM, Crowley JJ, Minasian LM, Klein EA, Cook ED, Darke AK, Arnold KB, Anderson K, Yee M, Meyskens FL, Baker LH. Moving a randomized clinical trial into an observational cohort. Clin Trials. 2013 Feb;10(1):131-42. doi: 10.1177/1740774512460345. Epub 2012 Oct 12. PMID: 23064404.

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41. doi: 10.1093/jnci/djt174. Epub 2013 Jul 10. PMID: 23843441

Dellinger RW, Garcia AM, Meyskens FL Jr. Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab Pharmacokinet. 2014;29(2):112-9. Epub 2013 Aug 20. PMID: 23965644.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014 Mar;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22. PMID: 24563519.

Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner N, Brown PH, Meyskens FL, Thompson IM. Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep;7(9):886-95. doi: 10.1158/1940-6207.CAPR-14-0058. Epub 2014 Jun 24. PMID: 24961880.

Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014 May;7(5):496-504. doi: 10.1158/1940-6207.CAPR-13-0189. Epub 2014 Mar 10. PMID: 24614012.

Kristal AR, Till CA, Song X, Tangen CM, Goodman PJ, Neuhouser ML, Schenk JM, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA. Plasma Vitamin D and Prostate Cancer Risk; Results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1494-504. doi: 10.1158/1055-9965.EPI-14-0115. Epub 2014 Apr 14. PMID: 24732629.

Yang Z, Yang S, Misner BJ, Liu-Smith F, Meyskens FL. The role of APE/Ref-1signaling pathway in hepatocellular carcinoma progression. Int J Oncol. 2014 Nov;45(5):1820-8. doi: 10.3892/ijo.2014.2589. Epub 2014 Aug 8. PMID: 25109342.

Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr. Factors associated with adherence to an end-of-study biopsy: lessons from the prostatecancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202. Epub 2014 Jul 15. PMID: 25028457.

Huang H, Li H, Yang S, Chreifi G, Martasek P, Roman LJ, Meyskens FL, Poulos TL, Silverman RB. Potent and selective double-headed thiophene-2-carboximidamide inhibitors of neuronal nitric oxide synthase for the treatment of melanoma. J Med Chem. 2014 Feb 13;57(3):686-700. doi: 10.1021/jm401252e. Epub 2014 Jan 30. PMID: 24447275.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Drager BJ, Schroder FH, Stenzl A, Tombal B, Wilt TJ, Wolk AQ. Prevention and early detection of prostate cancer. Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. PMID: 25281467.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204. PMID: 25738668.

Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A,Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM. A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci of the Colorectum. Cancer Prev Res (Phila). 2015 Mar;8(3):222-30. doi: 10.1158/1940-6207.CAPR-14-0148. Epub 2015 Jan 20. PMID: 25604134.

Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. Ann Oncol. 2015 Jan;26(1):47-57. doi: 10.1093/annonc/mdu225. Epub 2014 Aug 5. PMID: 25096604.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo Controlled Trial of Omega-3Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4. PMID: 25940724.

Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, LewDL, Hansen LK, Meyskens FL Jr, Wade JL 3rd, Hershman DL. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-relaated Joint Symptoms in Brease Cancer Patients. J Acupunct Meridian Stud. 2015 Jun;8(3):152-8. doi: 10.1016/j.jams.2015.03.006. Epub 2015 Apr 23. PMID: 26100070.

Morgan TR, Osann K, Bottiglieri T, Pimstoone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonsalez R, Rodriquez LM, Meyskens FL. A Phase II Randomized, Controlled Trial of S-Adenosyllmethionine in Reducing Serum a-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev Res (Phila). 2015 Sep;8(9):864-72. doi: 10.1158/1940-6207.CAPR-15-0029. Epub 2015 Jun 30. PMID: 26130251.

Meyskens FL Jr, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv309. doi: 10.1093/jnci/djv309. Print 2016 Feb. PMID: 26547931.

Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL. Opportunities and Challenges in Incorporating Ancillary Studies into a Cancer Prevention Randomized Clinical Trial. Trials. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9. PMID: 27519183.

Dellinger RW, Meyskens FL Jr. Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells. Methods Mol Biol. 2016 Jan 20. [Epub ahead of print]. PMID: 26786882.

Fabian CJ, Meyskens FL Jr (co-first author), Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr. Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations from the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. J Clin Oncol. 2016 Jan 10;34(2):186-93. doi: 10.1200/JCO.2015.63.5979. Epub 2015 Nov 2. PMID: 26527778.

Liu-Smith F, Meyskens F. Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma. Mol Nutr Food Res. 2016 Jun;60(6):1264-74. doi: 10.1002/mnfr.201500822. Epub 2016 Mar 21. PMID: 26865001.

Liu-Smith F, Krasieva TB, Liu J, Liu J, Meyskens FL Jr. Measuring Redox Status of Melanoma Cells. Methods Mol Biol. 2016 Apr 10. [Epub ahead of print]. PMID: 27062599.

Berwick M, Buller DB, Cust A, Gallagher R, Lee TK, Meyskens F, Pandey S, Thomas NE, Veierød MB, Ward S. Melanoma Epidemiology and Prevention. Cancer Treat Res. 2016;167:17-49. doi: 10.1007/978-3-319-22539-5_2. PMID: 26601858.

Liu-Smith F, Farhat AM, Arce A, Ziogas A, Taylor T, Wang Z, Yourk V, Liu J, Wu J, McEligot AJ, Anton-Culver H, Meyskens FL. Sex Differences in the Association of Cutaneous Melanoma Incidence Rates and Geographic Ultraviolet Light Exposure. J Am Acad Dermatol. 2017 Mar;76(3):499-505.e3. doi: 10.1016/j.jaad.2016.08.027. Epub 2016 Oct 26. PMID: 28413057.

Yuan TA, Yourk V, Farhat A, Ziogas A, Meyskens FL, Anton-Culver H, Liu-Smith F. A Case-Control Study of the Genetic Variability in Reactive Oxygen Species-Metabolizing Enzymes in Melanoma Risk. Int J Mol Sci. 2018 Jan 14;19(1). pii: E242. doi: 10.3390/ijms19010242. PMID: 29342889.

Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL Jr, Andresen BT, Huang Y. Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. Cancer Prev Res (Phila). 2017 Oct;10(10):598-606. doi: 10.1158/1940-6207.CAPR-17-0132. Epub 2017 Aug 15. PMID: 28912118.

Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL Jr, Liu-Smith F, Filipp FV. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. BMC Syst Biol. 2018 Apr 4;12(1):33. doi: 10.1186/s12918-018-0554-1. PubMed PMID: 29615030.

Blanke C, LeBlanc M, Hershman D, Ellis L, Meyskens F. Characterizing 18 Years of the Death With Dignity Act in Oregon. JAMA Oncol. 2017 Oct 1;3(10):1403-1406. doi: 10.1001/jamaoncol.2017.0243. PMID: 28384683.

Armstrong, W., Taylor, T, Meyskens, F.L., Jr. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers, Cancer Epidemiology, Biomarkers& Prevention Vol. 12, p589-592, 2003.

Meyskens, F.L., Jr. Anton-Culver, H., Yang, S., Fruehauf, J. Melanoma and Redox: ”A riddle wrapped in a mystery inside an enigma”. Society of Melanoma Research Online Newsletter. 2006

Meyskens, F.L., Jr. Young, A.R., Berwick, M. Cutaneous Malignant Melanoma: What Is the Role of Ultraviolet Radiation? Journal of Clinical Oncology Educational Book Feb. 6, (16) 2006

Meyskens, F.L., Jr. Ransohoff, D.F. Predicting Risk for the Appearance of Melanoma. Journal of Clinical Oncology 24: 3522-3533, 2006.

Fruehauf, J.P., Meyskens, F.L., Jr. Reactive oxygen species: a breath of life or death? Clin. Cancer Res 2007 Feb 1;13(3):789-94. Review

Meyskens FL Jr. Food extracts for chemoprevention: quo vadis? Cancer Prev Res (Phila). 2009 Jul;2(7):608-10. doi: 10.1158/1940-6207.CAPR-09-0102. PMID: 19584073.

Meyskens, FL Jr., McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst. 2010 Dec 15;102(24):1815-7. doi: 10.1093/jnci/djq466. Epub 2010 Nov 29. PMID: 21115881.

Garcia AM, McLaren CE, Meyskens FL Jr. Melanoma: is hair the root of the problem? Pigment Cell Melanoma Res. 2011 Feb;24(1):110-8. doi: 10.1111/j.1755-148X.2010.00782.x. Epub 2010 Oct 21. PMID: 20880199.

Meyskens FL. Jr, Gerner EW. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach. Cancer Prev Res (Phila). 2011 May;4(5):628-32. doi: 10.1158/1940-6207.CAPR-11-0162. PMID: 21543341.

Meyskens, FL, Jr. Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals. Cancer Prev Res (Phila). 2016 Jan;9(1):11-2. Doi: 10.1158/1940-6207.CAPR-15-0401. Epub 2015 Dec 23. PubMed PMID: 26527778.

Meyskens FL Jr. What to Do With the Participants/ Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA. J Natl Cancer Inst. 2016 Dec 16; 108 (12). Pii: djw252. PubMed PMID: 27986883.

Meyskens FL Jr., Liu-Smith F. Redox-Redux and NADPH Oxidase (NOX): Even More Complicated than We Thought it Might Be. J Invest Dermatol. 2017 Jun;137(6):1208-1210. doi: 10.1016/j.jid.2017.01.019. Review. PubMed PMID: 28532757.
Professional Societies
American Society of Clinical Oncology (ASCO)
Southwest Oncology Group (SWOG)
Medical Oncology Association of Southern California (MOASC)
Other Experience
Assistant -> Full Professor
University of Arizona 1977—1985

Associate Director of Cancer Prevention and Control
University of Arizona, Cancer Center 1985—1989

1989 Professor (Level III) -> Above Scale
University of California, Irvine 2009

Cancer Center Director
University of California, Irvine 1989—2013

Chief Hematology/Oncology
University of California, Irvine 1989—1997

Associate Dean of Research
University of California, Irvine, School of Medicine 2000—2004

Senior Associate Dean of New Programs
University of California, Irvine, School of Medicine 2004—2009

Senior Associate Vice Chancellor
University of California, Irvine, School of Medicine 2006—2009

Vice Dean of Research
University of California, Irvine, School of Medicine 2009—2013

Graduate Programs
Cancer Biology

Public Health

Pharmacological Sciences


Research Center
Chao Family Comprehensive Cancer Center
Last updated